HCPCS Level II code J2175 denotes an injectable dose of meperidine hydrochloride, billed per 100 mg. As a drug-specific HCPCS code, it is used to report parenteral administration of meperidine in acute and outpatient care settings where injectable opioid analgesics are provided. This code matters nationally because it enables standardized reporting and reimbursement for meperidine use across hospitals, emergency departments, ambulatory surgery centers, and clinics.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for meperidine use, typical sites of service, and the role of HCPCS coding in drug billing. The publication outlines benchmark considerations for per-unit billing, payer coverage patterns (where available), and common administrative practices tied to injectable pharmaceuticals.

The report provides actionable reference material for billing professionals and revenue cycle staff: how J2175 is recorded on claims, the service settings where it commonly appears, and the elements payers review when adjudicating meperidine injections. Data not available in the input is identified explicitly where applicable, and the content focuses on national implications rather than state-level details.